Financial Comparison: Enveric Biosciences (NASDAQ:ENVB) and MediciNova (NASDAQ:MNOV)

MediciNova (NASDAQ:MNOV) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Volatility and Risk

MediciNova has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Enveric Biosciences has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.

Institutional & Insider Ownership

9.9% of MediciNova shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 14.0% of MediciNova shares are owned by company insiders. Comparatively, 2.4% of Enveric Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares MediciNova and Enveric Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,962.98%	-27.28%	-25.24%
Enveric Biosciences	N/A	-220.97%	-177.47%

Analyst Recommendations

This is a summary of current ratings for MediciNova and Enveric Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1	1	3	1	2.67
Enveric Biosciences	1	0	0	0	1.00

MediciNova currently has a consensus target price of $8.33, suggesting a potential upside of 536.13%. Given MediciNova’s stronger consensus rating and higher probable upside, equities analysts plainly believe MediciNova is more favorable than Enveric Biosciences.

Valuation & Earnings

This table compares MediciNova and Enveric Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410,000.00	157.26	-$12.00 million	($0.23)	-5.70
Enveric Biosciences	N/A	N/A	-$8.77 million	($23.54)	-0.06

Enveric Biosciences has lower revenue, but higher earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

MediciNova beats Enveric Biosciences on 9 of the 14 factors compared between the two stocks.

About MediciNova

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

About Enveric Biosciences

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.